John Lacey - BioLine RX Head Relations
| BLRX Stock | ILS 10.50 3.50 25.00% |
Insider
John Lacey is Head Relations of BioLine RX
| Phone | (972) 8 642 9101 |
| Web | www.biolinerx.com |
BioLine RX Management Efficiency
The company has return on total asset (ROA) of (0.2029) % which means that it has lost $0.2029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3721) %, meaning that it generated substantial loss on money invested by shareholders. BioLine RX's management efficiency ratios could be used to measure how well BioLine RX manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ariel Genut | The Phoenix Holdings | N/A | |
| Hila Conforti | Clal Insurance Enterprises | 60 | |
| Moshe Morgenstern | Menora Miv Hld | 46 | |
| Roni Libersohn | Migdal Insurance | N/A | |
| Itay Weinstein | XTL Biopharmaceuticals | 52 | |
| Nataly MishanZakai | Harel Insurance Investments | 49 | |
| Israel Feldinger | Israel Opportunity | 35 | |
| Advocate IrShai | Menora Miv Hld | 64 | |
| Asaf Shaham | Migdal Insurance | 54 | |
| Moni Feller | The Phoenix Holdings | N/A | |
| Yosef Dori | Clal Insurance Enterprises | 52 | |
| Ari Kalman | Menora Miv Hld | 72 | |
| Stein Sagi | Migdal Insurance | 47 | |
| Eran Cherninsky | Clal Insurance Enterprises | 61 | |
| Tami Koll | Migdal Insurance | 48 | |
| Eyal Simon | The Phoenix Holdings | 50 | |
| Ronen Kantor | XTL Biopharmaceuticals | N/A | |
| Uri Aldubi | Israel Opportunity | 58 | |
| Liat Strauss | Clal Insurance Enterprises | 45 | |
| Nir Cohen | Harel Insurance Investments | 52 | |
| Ran Givon | The Phoenix Holdings | N/A | |
Management Performance
| Return On Equity | -0.37 | |||
| Return On Asset | -0.2 |
BioLine RX Leadership Team
Elected by the shareholders, the BioLine RX's board of directors comprises two types of representatives: BioLine RX inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioLine. The board's role is to monitor BioLine RX's management team and ensure that shareholders' interests are well served. BioLine RX's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioLine RX's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Ella Sorani, Vice President - Development | ||
| Raziel Fried, Treasurer Director | ||
| Jael MSc, QA RA | ||
| CPA MBA, Chief Officer | ||
| Holly MBA, Pres USA | ||
| Advocate Kotler, Gen Officer | ||
| Liron MBA, Director Devel | ||
| John Lacey, Head Relations | ||
| Abi MD, Chief Officer | ||
| LLB BSc, Head Advisor |
BioLine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioLine RX a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | (13.02 M) | |||
| Shares Outstanding | 922.87 M | |||
| Shares Owned By Insiders | 0.25 % | |||
| Shares Owned By Institutions | 0.10 % | |||
| Price To Book | 0.77 X | |||
| EBITDA | (25.37 M) | |||
| Net Income | (27.05 M) | |||
| Cash And Equivalents | 40.61 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BioLine Stock
BioLine RX financial ratios help investors to determine whether BioLine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLine with respect to the benefits of owning BioLine RX security.